Fate Therapeutics Inc (NASDAQ: FATE) is 83.69% higher on its value in year-to-date trading and has touched a low of $1.63 and a high of $8.83 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The FATE stock was last observed hovering at around $6.61 in the last trading session, with the day’s gains setting it 0.26%.
Currently trading at $6.87, the stock is -7.32% and 6.94% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.99 million and changing 3.93% at the moment leaves the stock 72.52% off its SMA200. FATE registered 31.36% gain for a year compared to 6-month gain of 225.59%. The firm has a 50-day simple moving average (SMA 50) of $8.51 and a 200-day simple moving average (SMA200) of -$3.14.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -1.29% loss in the last 1 month and extending the period to 3 months gives it a 105.07%, and is -2.41% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 9.81% over the week and 10.49% over the month.
Fate Therapeutics Inc (FATE) has around 181 employees, a market worth around $681.78M and $63.53M in sales. Profit margin for the company is -253.30%. Distance from 52-week low is 321.47% and -22.20% from its 52-week high. The company has generated returns on investments over the last 12 months (-34.55%).
Fate Therapeutics Inc quarterly earnings per share for the current quarter are estimated at -$0.49 with sales reaching $1.2M over the same period.The EPS is expected to shrink by -15.94% this year, but quarterly earnings will post -93.20% year-over-year. Quarterly sales are estimated to shrink -98.00% in year-over-year returns.
Fate Therapeutics Inc (FATE) Top Institutional Holders
227 institutions hold shares in Fate Therapeutics Inc (FATE), with institutional investors hold 93.36% of the company’s shares. The shares outstanding are 98.63M, and float is at 86.74M with Short Float at 15.55%. Institutions hold 91.98% of the Float.
The top institutional shareholder in the company is Redmile Group, LLC with over 13.17 million shares valued at $90.47 million. The investor’s holdings represent 13.27% of the FATE Shares outstanding. As of Dec 30, 2023, the second largest holder is Blackrock Inc. with 11.21 million shares valued at $77.03 million to account for 11.30% of the shares outstanding. The other top investors are Vanguard Group Inc which holds 9.29 million shares representing 9.36% and valued at over $63.85 million, while Bellevue Group AG holds 4.89% of the shares totaling 4.85 million with a market value of $33.33 million.
Fate Therapeutics Inc (FATE) Insider Activity
The most recent transaction is an insider sale by Dulac Edward J III,the company’sChief Financial Officer. SEC filings show that Dulac Edward J III sold 2,447 shares of the company’s common stock on Mar 04 ’24 at a price of $7.77 per share for a total of $19013.0. Following the sale, the insider now owns 0.1 million shares.
Fate Therapeutics Inc disclosed in a document filed with the SEC on Jan 29 ’24 that Dulac Edward J III (Chief Financial Officer) sold a total of 1,849 shares of the company’s common stock. The trade occurred on Jan 29 ’24 and was made at $5.00 per share for $9245.0. Following the transaction, the insider now directly holds 0.1 million shares of the FATE stock.
Still, SEC filings show that on Jan 09 ’24, Wolchko J Scott (President and CEO) disposed off 14,391 shares at an average price of $4.37 for $62889.0. The insider now directly holds 371,248 shares of Fate Therapeutics Inc (FATE).
